CD8A and neoplasm: Specifically, administration of either a PI3Kγ inhibitor or BTK inhibitor (ibrutinib) to PDAC-bearing mice repolarized TAMs towards a Th1 phenotype and led to CD8+ T cell cytotoxicity and reduced tumor burden.